✦ LIBER ✦

N92 Sequential high-dose chemotherapy with hematopoietic stem-cell support in poor risk, relapsed or refractory germ-cell tumor patient treatment: Lithuanian experience

✍ Scribed by J. Korsakas; K. Andrekute-Aleksiejiene; A. Bukauskas; B. Brasiuniene; I. Trociukas; F. Jankevicius; L. Griskevicius

Book ID: 119620426
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 73 KB
Volume: 8
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(09)74866-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose chemotherapy with hematopoieti

High-dose chemotherapy with hematopoietic stem-cell support in germ-cell tumor patient treatment: The French experience

✍ A. Fléchon; P. Biron; J.P. Droz 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 105 KB 👁 2 views

## Germ -cell tumors (GCTs) are very chemosensitive and highly curable cancers. For the small proportion of patients who fail conventional chemotherapy (CT), high-dose CT (HDCT) was introduced in France and elsewhere in 1982-1984. We report here on the French experience with HDCT in GCTs. At the C

High-dose chemotherapy with haematopoiet

High-dose chemotherapy with haematopoietic stem-cell support in patients with poor prognosis, relapsed or refractory germ cell tumours

✍ LOAIE M. EL-HELW; JAY D. NAIK; JOHN D. CHESTER; JOHNATHAN K. JOFFE; PETER J. SEL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB

Gemcitabine, Busulfan and Melphalan (Gem

Gemcitabine, Busulfan and Melphalan (Gem/Bu/Mel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity in Refractory or Poor-Risk Relapsed Non-Hodgkin'S Lymphoma (NHL) Patients Receiving an Autologous Stem-Cell Transplant (ASCT)

✍ Y. Nieto; R.B. Jones; U. Popat; B. Andersson; B. Valdez; P. Thall; E.J. Shpall; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 56 KB

High-dose chemotherapy using BEAM for tu

High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma

✍ Buser, A S; Heim, D; Bucher, C; Tichelli, A; Gratwohl, A; Passweg, J R 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 101 KB